Cervical cancer

New Data Shows That Engaging Patients with Relevant Cancer-Prevention Information During Check-In Increases Screening Rates

Retrieved on: 
Tuesday, February 20, 2024
Technology, Other Communications, Public Relations, Investor Relations, Other Technology, Communications, Health, General Health, Data Management, Oncology, Smoking, Breast cancer, Lung cancer, Breast, Cervical cancer, Woman, COVID-19, Risk, Doctor of Philosophy, Death, Colorectal cancer, Patient, Cancer, SVP

The analysis revealed that when patients were shown relevant and accurate cancer prevention information while checking in for a visit with their doctor, they found the information helpful and said they would discuss preventive screenings with their doctor or request appointments.

Key Points: 
  • The analysis revealed that when patients were shown relevant and accurate cancer prevention information while checking in for a visit with their doctor, they found the information helpful and said they would discuss preventive screenings with their doctor or request appointments.
  • “We underestimate the lifesaving value of clear communications directly to patients about the importance of cancer screenings,” said Hilary Hatch, PhD, a clinical psychologist and Phreesia’s Chief Clinical Officer.
  • One health system asked more than 87,000 patients about mammogram screenings, and 32% of them requested a mammogram appointment.
  • "We believe that engaging patients with high-quality and relevant information about their health results in better health outcomes," said David Linetsky, SVP, Life Sciences, at Phreesia.

Leading Cervical Cancer Doctors Support Approval of LuViva in China Based on Preliminary Review of Clinical Trial Results

Retrieved on: 
Tuesday, February 20, 2024
Other Health, Research, General Health, Oncology, Consumer, Medical Devices, Clinical Trials, Science, Women, Biotechnology, Medical Supplies, Health, OTCQB, Hospital, Cervical cancer, Fudan University, SMI, Physician, Shandong University, Chinese, Therapy, Statistics, NMPA, Pharmaceutical industry

Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that a group of prominent cervical cancer doctors are in the final stages of completing the clinical data report that will be submitted for approval by the Chinese National Medical Products Administration (NMPA).

Key Points: 
  • Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that a group of prominent cervical cancer doctors are in the final stages of completing the clinical data report that will be submitted for approval by the Chinese National Medical Products Administration (NMPA).
  • The data quality assurance review team is being led by Dr. Sui Long, Director of the Gynecology Hospital at Fudan University and includes physicians from Qilu Hospital at Shandong University and two hospitals in Shanghai.
  • The quality assured data report is expected by the end of this month with final statistics from the study to be available early in March.
  • SMI’s CEO, Mr. Yaohua Li reported that “We already have pre-orders from multiple provinces in China for nearly 100 devices and thousands of disposables.

Summary of opinion: Keytruda, 22/02/2024 Positive

Retrieved on: 
Sunday, March 10, 2024
Carboplatin, GEJ, Hodgkin lymphoma, Patient, HNSCC, Cervical cancer, Ageing, CHL, Colorectal cancer, ALK, BTC, Head, Large intestine, Neck, Committee, Recurrence, IIC, Marketing, RCC, Renal cell carcinoma, Cancer, TPS, CHMP, Trastuzumab, TNBC, Paclitaxel, ASCT, Axitinib, Transitional epithelium, NSCLC, Lung cancer, European Commission, EGFR, Cholangiocarcinoma, Medication package insert, CRC, Neoplasm, Radiation, Cisplatin, Civil service commission, Pembrolizumab, Endometrial cancer, Nephrectomy, Platinum, MSI-H, Pemetrexed, Bevacizumab, Risk, Transitional cell carcinoma, CPS, PD-L1

Summary of opinion: Keytruda, 22/02/2024 Positive

Key Points: 


Summary of opinion: Keytruda, 22/02/2024 Positive

Hybribio Calls for Raising International HPV Awareness

Retrieved on: 
Monday, March 4, 2024
International, Hospital, Cervical cancer, Woman, IPVS, SOX1, Methylation, Cancer, Human papillomavirus infection, Wart, Vaccination, World Health Organization, Fluorescence, Organization, HPV, Vagina, WHO, PCR, NMPA

On this special day, Hybribio (300639.SZ) calls for raising international HPV awareness and adopting effective strategies for early detection and prevention.

Key Points: 
  • On this special day, Hybribio (300639.SZ) calls for raising international HPV awareness and adopting effective strategies for early detection and prevention.
  • In this case, raising HPV awareness, getting timely vaccination and high-quality screening together contribute significantly to the prevention of HPV infection and related diseases.
  • Hybribio has developed a complete HPV molecular diagnostic solution covering 14 High-risk HPV GenoArray Diagnostic Kit, 14 High-risk HPV with 16/18 Genotyping Real-time PCR Kit, 14 High-risk HPV E6/E7 mRNA Real-time PCR Kit (PCR with Fluorescent Probe), 21 HPV GenoArray Diagnostic Kit, 37 HPV GenoArray Diagnostic Kit, 13 High-risk HPV Real-time PCR Kit, 23 HPV Genotyping Real-time PCR Kit, SOX1 and PAX1 Methylation Real-time PCR Kit.
  • Raising international HPV awareness is the very first step against cervical cancer.

Hybribio Calls for Raising International HPV Awareness

Retrieved on: 
Monday, March 4, 2024
International, Hospital, Cervical cancer, Woman, IPVS, SOX1, Methylation, Cancer, Human papillomavirus infection, Wart, Vaccination, World Health Organization, Fluorescence, Organization, HPV, Vagina, WHO, PCR, NMPA

On this special day, Hybribio (300639.SZ) calls for raising international HPV awareness and adopting effective strategies for early detection and prevention.

Key Points: 
  • On this special day, Hybribio (300639.SZ) calls for raising international HPV awareness and adopting effective strategies for early detection and prevention.
  • In this case, raising HPV awareness, getting timely vaccination and high-quality screening together contribute significantly to the prevention of HPV infection and related diseases.
  • Hybribio has developed a complete HPV molecular diagnostic solution covering 14 High-risk HPV GenoArray Diagnostic Kit, 14 High-risk HPV with 16/18 Genotyping Real-time PCR Kit, 14 High-risk HPV E6/E7 mRNA Real-time PCR Kit (PCR with Fluorescent Probe), 21 HPV GenoArray Diagnostic Kit, 37 HPV GenoArray Diagnostic Kit, 13 High-risk HPV Real-time PCR Kit, 23 HPV Genotyping Real-time PCR Kit, SOX1 and PAX1 Methylation Real-time PCR Kit.
  • Raising international HPV awareness is the very first step against cervical cancer.

FDA Grants Fast Track Designation to 9MW2821

Retrieved on: 
Tuesday, February 27, 2024
DCR, Carcinoma, Immunotherapy, Cervical cancer, FDA, Food, ESCC, Fast track (FDA), PD-1, Apoptosis, ADC, FTD, UC, Cell membrane, Patient, Esophageal cancer, Fine chemical

SHANGHAI, Feb. 27, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announces that its self-developed novel ADC drug targeting Nectin-4 (R&D Code: 9MW2821) has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of advanced, recurrent, or metastatic esophageal squamous cell carcinoma (hereinafter referred to as "ESCC").

Key Points: 
  • SHANGHAI, Feb. 27, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announces that its self-developed novel ADC drug targeting Nectin-4 (R&D Code: 9MW2821) has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of advanced, recurrent, or metastatic esophageal squamous cell carcinoma (hereinafter referred to as "ESCC").
  • 9MW2821 is the world's first Nectin-4-targeting drug to disclose clinical efficacy data for the indication of EC.
  • After injection, 9MW2821 can specifically bind to Nectin-4 on the cell membrane surface, be internalized and release cytotoxic drug, and induce the apoptosis of tumor cells.
  • 9MW2821 is also the first to disclose preliminary clinical efficacy data for the indication of CC among drugs with the same target in the world.

BD Partners with Camtech Health to Increase Access to Cervical Cancer Screening in Singapore

Retrieved on: 
Wednesday, February 21, 2024
Gynaecology, Audiolab, Cervical cancer, Woman, Embarrassment, Commonwealth, FDA, Cancer, Health, IOS, Human papillomavirus infection, Death, Risk, Medicine, Vaccination, Obstetrics, World Health Organization, Fear, BDX, Android, Virus, Public, Privacy, HPV, Adviser, WHO, Elimination, Partnership, Birth control

SINGAPORE, Feb. 21, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic partnership with Camtech Health, a digital health company focused on at-home health testing, to advance cervical cancer screening by offering the first-ever option for women in Singapore to self-collect a sample in the privacy of their own home.

Key Points: 
  • The program objective is to improve the rate of cervical cancer screening in Singapore, where less than half of eligible women are currently being tested.
  • "Cervical cancer is preventable, precancer is curable, and programs like this help to support the national goal of cervical cancer elimination.
  • In late 2020, the World Health Organization (WHO) launched its Global Strategy to Accelerate the Elimination of Cervical Cancer, recognizing the potential to virtually eliminate cervical cancer as a public health threat, recognizing the potential to eliminate cervical cancer in our lifetimeiii.
  • At-home collection can help address the urgent public health challenge of reaching women who do not attend routine cervical cancer screening.

Cervical Cancer Studies Outline Innovative Treatment Options For Patients In 2024

Retrieved on: 
Thursday, February 15, 2024
Cervical cancer, Research, IIB, Disability, Chemoradiotherapy, CCRT, Social, Vaccination, Risk, Survival rate, Social Security, DFS, SSDI, Patient, Social Security Disability Insurance, Survival, Disease, HPV, Ageing, Cancer, Birth control

Research highlights the critical link between HPV (human papillomavirus) and cervical cancer, with the virus responsible for the majority of cases.

Key Points: 
  • Research highlights the critical link between HPV (human papillomavirus) and cervical cancer, with the virus responsible for the majority of cases.
  • Regular cervical cancer screening is essential for those aged 21 to 65, incorporating HPV testing followed by further assessments for those with positive results.
  • In evaluating treatment efficacy for stage IB2 to IIB cervical carcinoma, a 12-year study involving 626 patients compared neoadjuvant chemotherapy followed by surgery (NACT-S) with concomitant chemoradiotherapy (CCRT).
  • Cervical Cancer Awareness Month is a crucial time to raise public awareness about cervical cancer and the importance of early detection and treatment.

Oakland Roasting Pioneer, Peerless Coffee & Tea, Celebrates 100th Anniversary

Retrieved on: 
Tuesday, February 6, 2024
Coffee, Availability, Centennial, Roasting, Fair trade, Organic certification, San Francisco Bay Area, Soil, Carbon, Oakland Museum of California, Cervical cancer, Certification, Name, Peerless, Female, Farmer, Boy, Empowerment, Folgers, Health, Coffeehouse, Face, Woman

OAKLAND, Calif., Feb. 6, 2024 /PRNewswire-PRWeb/ -- Third-generation family owned-and-operated Oakland-based coffee roaster Peerless Coffee & Tea will mark their 100th anniversary this year with a series of celebrations and events. To kick off this momentous occasion, Peerless is giving away 100 cups of coffee at their cafe in Oakland's warehouse district on Friday, February 23, 2024 (located at 260 Oak St., Oakland, CA, open 7 a.m. - 4 p.m.). This will mark the start of their "Peerless Acts of Giving" initiative, which will also include Peerless donating 100 cents from every cup and pound of coffee sold on the first Friday of every month to the Boys & Girls Clubs of Oakland (beginning Friday, March 1, and continuing throughout 2024).

Key Points: 
  • OAKLAND, Calif., Feb. 6, 2024 /PRNewswire-PRWeb/ -- Third-generation family owned-and-operated Oakland-based coffee roaster Peerless Coffee & Tea will mark their 100th anniversary this year with a series of celebrations and events.
  • "We have not just survived a hundred years, but, in the face of today's increasingly competitive coffee landscape, Peerless continues to thrive."
  • As part of the anniversary, Peerless is also excited to announce the release of their first ROC® (Regenerative Organic Certified) coffee blend, which represents the next frontier in sustainable coffee, and reflects the brand's legacy of innovation.
  • bag)
    Peerless will continue to announce additional events tied to its anniversary and the Peerless Act of Giving initiative throughout 2024.

Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer

Retrieved on: 
Friday, February 2, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, OS, PFS, Patient, Progression-free survival, EMA, MAA, Marketing, Cervical cancer, ADC, European Medicines Agency, Woman, Pharmaceutical industry

Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE PFE) today announced that the European Medicines Agency (EMA) has validated for review the marketing authorization application (MAA) of tisotumab vedotin, an antibody-drug conjugate (ADC), developed for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.

Key Points: 
  • Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE PFE) today announced that the European Medicines Agency (EMA) has validated for review the marketing authorization application (MAA) of tisotumab vedotin, an antibody-drug conjugate (ADC), developed for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.
  • If approved, tisotumab vedotin would be the first ADC granted European Union (EU) marketing authorization for people living with cervical cancer.
  • Data from the innovaTV 204 pivotal Phase 2 single-arm clinical trial evaluating TIVDAK as monotherapy in patients with previously treated recurrent or metastatic cervical cancer was also included in the MAA.
  • The safety profile of tisotumab vedotin in innovaTV 301 was consistent with its known safety profile as presented in the U.S. prescribing information.